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Isoantigens  of  the  TL  (thymus-leukemia)  system  are  determined  by the 
locus Tla adjacent to H-2 in linkage  groups IX (1). In normal mice,  they are 
to be regarded as organ-specific  isoantigens  because they are found exclusively 
in one cell type, the thymocyte, and are present in some strains of mice (TL+ 
strains)  hut absent in others (TL--  strains). The system is of special  interest 
in relation  to neoplasia because of the anomalous appearance of TL antigen 
in  leukemi~s  of TL--  mice;  ie,  mice whose thymocytes do not  contain  TL 
antigen and which therefore are capable of forming TL antibody (2). 
Table I  summarizes our knowledge of the phenotypes known to be expressed in thymo- 
cytes and leukemia cells.  Three antigens of the Tla locus have been identified, TL.I, TL.2, 
and  TL.3.  TL+  mice have one of two  phenotypes,  TL.2  or TL.1,2,3.  The  components 
which occur anomalously in leukemia cells are TL.1 and TL.2; TL.3 occurs only in leukemias 
of TL.1,2,3  mice. It follows that leukemia cells may have the phenotype  (a)  TL--  in any 
strain,  (b) TL.1,2 in TL-- or TL.2 strains, or (c) TL.1,2,3 in TL.1,2,3 strains. Regarding 
the anomalous appearance of TL.I and 2 in leukemia cells, we conclude that all mice have 
the structural genes for synthesis of these antigens,  their expression in the thymocytes of 
normal mice being dependent on a controlling gene or genes belonging to the Tin locus with 
alleles for expression vs. nonexpression. Experiments with radiation  chimeras indicate that 
the controlling gene exerts its effect directly within the cells which populate the thymus and 
not indirectly through an influence of the thymus (3). In leukemia cells, loss of normal control 
over TL phenotype is evident in two ways. First, TL+  cells now are disseminated in organs 
other than the thymus. Secondly, TL antigens 1 and 2 are found expressed  in TL-- mice. 
The realization  that  TL+  leukemias occur in  TL--  mice, which  are  capable of being 
immunized against TL antigens and of forming high titers of cytotoxic TL antibody, initially 
raised the possibility of active immunization against such leukemias within the inbred strain 
of origin. It was later recognized that this is rendered impracticable by the occurrence of a 
phenomenon called "antigenic modulation"  (4).  Mice of TL-- strains produce TL antibody 
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when  immunized  with  allogeneic TL+  leukemia  cells;  when  syngeneic TL+  leukemias 
are now passed in such previously immunized hosts, TL antigen is suppressed and the cells 
are no longer sensitive to cytotoxic TL antibody and  complement. This disappearance  of 
TL antigen and  its reappearance on subsequent  passage in nonimmune hosts,  are referred 
to as antigenic modulation. It can be produced passively by the transfer of TL antiserum, 
either by injection or by suckling on immune mothers, and  it occurs in TL+  thymocytes 
as well as in leukemia cells  (5). 
TABLE I 
Summary of All Known Phenotypes of Thymocytes and Leukemia Cdls 
Deslgnafion of mouse strain  Phenotypes of leukemlas in mice 
(= phenotype of normal thymocytes)  with phenotypes shown on the left 
TL--  TL-- or TL.1,2 
TL.2,  TL-- or TL.1,2 
TL.1,2,3  TL-- or TL.1,2,3 
TABLE II 
TL Phenotypes of Mice and Leukemia,  s  Used in This Study 
Phenotype  Mouse strain  Transplanted leukemia 
TL-- 
TL.1,2 
TL.2 
TL.1,2,3 
C57BL/6, C3H 
BALB/c, 129 
A 
ERLD  (C57BL/6  radiation-induced 
leukemia) 
RADA1  (A  strain  ascites  leukemia: 
radiation-induced) 
ASL1 (A strMn spontaneous leukemia) 
In  order  to  facilitate  the  investigation  of  antigenic  modulation  we  have 
made a  study of its occurrence in vitro under conditions which lend themselves 
to  analysis  of the kind  that  is not feasible with modulation produced  in vivo. 
Materials and Methods 
M/ce.--These were obtained from our colonies;  TL phenotypes shown in Table II. 
Leukemlas.---Ori~ms and TL phenotypes given in Table II (see also reference 2). 
Antisera.--See Table III. 
Procedure for Modulation In Vitro.--The cells were washed in medium 199 and counted. 
Volumes of this suspension  containing the number of cells required were centrifuged at 800 
rpm increasing to 1200 rpm  (International Refrigerated Centrifuge Model PR-2; 269 Head) 
for 10 rain and the cells resuspended at a concentration of 5 X  106/ml in the desired medium. 
Incubation was carried out in stoppered bottles at 37°C in a water bath.  Exposure of the OLD~ STOCKERT~ BOYSE~ AND  KIM  525 
cell suspensions to an atmosphere of CO2 was found to be unnecessary in the case of leukemia 
cells as the acidity of the meditun was  maintained or more usually increased under these 
conditions. The bottles were shaken every 10 rain to keep the cells freely suspended. The 
medium was 199 with the addition of either normal mouse serum (NMS) or TL antiserum. 
In all cases a minimum of 5% mouse serum was maintained during incubation: thus 5% NMS 
was added to all suspensions in which the concentration of TL antiserum used was less than 
TABLE  III 
Antiscra 
TL 
Immunization  Absorption  Designation 
C57BL/6 anti-A strain 
leukemia ASL1 
(BALB/c X  C3H)F1 anti-A 
strain leukemia ASL1 
C57BL/6 anti-129 thymus 
In vivo in A  o  ~ cV  (removes anti- 
H-2a:  TL  antibody  is  not  ab- 
sorbed) 
Unnecessary: anti-TL  is the only 
demonstrable  antibody  formed 
In vivo in (C57BL/6 X  A)FI o~o  ~ 
bearing  advanced  transplants 
of  C57BL/6  leukemia  ERLD 
(TL.1,2).  Absorbed  serum  has 
no anti-TL.1  activity 
Unnecessary:  only  TL  antibody 
formed 
anti-TL.1,2,3 
anti-TL.1,3 
anti-TL.3 
anti-TL.2 
H-2 
Immunization  Test cell  Designation 
C3H/An anti-BALB/c ascites 
sarcoma Meth A 
(BALB/c X  C57BL/6)F~ 
anti-C3H ascites sarcoma 
BP8 
A strain lymph node cells 
A strain lymph node cells 
anti-H-2  (D) 
anti-H-2(K) 
5%. After the prescribed period of incubation the cells were immediately cooled in an ice bath 
to prevent or arrest modulation  (see Results) and were then washed twice; these washings 
and all procedures thereafter being carried out in the cold, except for subsequent cytotoxie 
tests and tests of sensitivity to complement  (C')  requiring incubation at 37°C. 
Cytoto~ Tests (6-8).--Serlal dilutions (0.05  ml) of antiserum were incubated with cells 
(0.05  ml of a  suspension containing 5 X  10  e cells/m1) and pooled absorbed guinea pig serum 
(GPS)  diluted  1/3  (0.05  ml) to provide C'. After incubation for 45 rain at 37°C  the cells 
were counted in trypan blue to determine the dead  (stained) cell count per cent. In every 
test, cells were incubated also in: (a) antiserum alone, and (b)  GPS alone; unless otherwise 
stated these controls showed no more than 10% stained cells. The diluent was medium 199. 526  ANTIGENIC  MODULATION 
A 
B 
The GPS was previously absorbed  twice in the cold with mouse leukemia cells to remove 
heteroantibody  (9 vol GPS: 1 vol packed cells;  X2). 
Relative 1t-2 Absorption Capaclty.--The two H-2 antisera shown in Table III were used 
for measurements of the H-2 content of RADA1 cells undergoing modulation (Fig; 7). 0.06 ml 
of H-2 antiserum  (dilution determined in preliminary experiments) was absorbed with 3  X 
106 RADA1 cells for 30  min in the cold with repeated shaking.  The absorbed  serum was 
titrated by the cytotoxic test against A  strain lymph node ceils.  The result was expressed 
as per cent A lymph node cells dead in a  cytotoxic test with the absorbed antiserum.  For 
Control 
Dilution of omi-[L.1, 3 serum in which cells were preincubated  (no antiserum) 
1/10  1/520  1/640  1/1280  t/2560  1/6120 
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Fro.  1.  Modulation of TL antigens induced in vitro by incubation of TL+  ceils in TL 
antiserum. RADA1 (TL.1,2,3) leukemia cells were exposed to concentrations of anti-TL.1,3 
serum ranging from 1/10 to 1/5120 for periods of 5 rain to 4 hr. The cells were then washed 
and tested (a) for the presence of TL antigen, by the cytotoxic test with TL -~mtiserum and 
guinea pig serum C'  (A),  and  (b)  for attached antibody, by addition of C' alone (B). 
The results show (a)  Dilutions 1/10-1/640: initial sensitization to C' followed by loss of 
sensitization to C' (B)  and progressive loss of TL antigen (A).  (b) Dilutions 1/1280-1/2560: 
no sensitization to C' (B)  and progressive loss  of TL antigen (A).  (c)  Dilution 1/5120 and 
control: no sensitization to C' (B)  and no loss of TL antigen  (A). 
each time interval  (Fig.  7)  this  value was  determined  for RADA1 cells incubated  in TL 
antiserum  (X) and for control RADAI ceils incubated in NMS (Y). An arbitrary index, the 
"relative H-2 absorption capacity" is given by Y/X. 
Incorporation of Labeled Precursors into Nucleic Acid and Proteins.--Equal volumes of a 
suspension  of RADA1  ceils  (6  X  105/ml)  were incubated  with thymidine-aH  (0.2 #c/ml, 
1.9 c/mmole), uridine-3I-I (1 ~c/ml, 8.0 e/mmole), or valine-SH  (2.0 ~c/ml, 290 mc/mmole) 
as a measure of DNA, RNA, and protein synthesis respectively. At specified  time intervals 
the ceils were collected and  filtered through Millipore membrane falters  (0.45/~ pore size). 
The filters were washed with cold 5% trichloroacetic acid and their radioactivity determined 
with a liquid scintillation spectrometer. OLD,  STOCKERT, BOYSE, AND  KIM  527 
RESULTS 
Antigenic Modulation In  Vitro.-- 
In initial experiments a  variety of TL+  cells were tested for their ability 
to undergo modulation in vitro. These showed that TL+ leukemia ceils readily 
become TL--  on exposure to TL antibody-,  whereas TL+  thymocytes modu- 
late very little even after several hours of exposure to TL antiserum. Of the 
several TL+  leukemias  tested,  the A  strain leukemia RADA1  was selected 
for further experiments on the grounds that it grows in the ascitic form, carries 
all three TL components, and undergoes modulation rapidly and completely 
in response to TL antibody. 
Fig. 1 shows an experiment in which RADA1 cells were incubated in various 
concentrations of anti-TL.1,3 serum for up to 4 hr. In the range 1/10-1/640 
modulation was complete within 90  rain;  ie,  at  this  time the cells  were no 
longer sensitive in the cytotoxic test with TL antiserum and C' (Fig.  1, A). 
In  these concentrations of TL antibody the cells were initially sensitized to 
lysis by C' but progressively lost their sensitivity on further incubation (Fig. 
1, B). In the range 1/1280-1/2560  modulation was incomplete and there was 
virtually no sensitization to C'. At a concentration of 1/5120 there was neither 
modulation nor sensitization to C'. The cytotoxic titer of this antiserum (50 % 
end point) for RADA1  cells was 1/256 under the standard conditions of the 
cytotoxic test, which are comparable with those of the modulation test. 
Inhibition of Antigenic Modulation.- 
These experiments were directed to  the question whether modulation is a 
passive process consequent on the attachment of TL antibody, or whether it 
requires active metabolic participation on the part of the cell. 
Influence of temperature: In Fig. 2 it is seen that reduction of the incubation 
temperature to 0°C completely inhibited modulation. This is not explained by 
failure of attachment of TL antibody at 0°C because the cells were fully sen- 
sitized to C' under these conditions (Fig. 2). At 22°C modulation was incom- 
plete. 
Effect  of metabolic inhibitors  and X-radiation: RADA1  cells were incubated 
for 1-2 hr at 37°C with various metabolic inhibitors and tested for their ability 
to undergo modulation when subsequently exposed to TL antibody. Two of 
these, actinomycin D  and iodoacetamide, completely inhibited modulation at 
concentrations that had no effect on viability during the period of the test 
(5 #g/ml in both cases).  The capacity of RADA1 cells to modulate was abol- 
ished by exposure to 5 ~zg/ml actinomycin D  for 1 hr; lesser concentrations, 
or  shorter  periods  of  exposure,  produced  proportionately  less  impairment 
(Fig. 3). The other compounds tested did not inhibit modulation, even in some 
instances at levels producing decreased viability in controls: puromycin (10 
/~g/ml  and  20  /~g/ml);  chloramphenicol  (100  /zg/ml);  p-fluorophenylalanine I00 
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Fro.  2.  Temperature-dependence of  antigenic modulation. Cytotoxic  tests with RADA1 
(TL.1,2,3)  leukemia cells previously incubated with  anti-TL.1,3  serum  1/10 for 2  hr at 
0°C  (ice bath), 22°C  (room temperature), or 37°C,  and washed twice in the cold.  Control: 
the per  cent  viability of  RADA1  cells after preincubation at  each  temperature remained 
>95. 
Modulation was complete  at 37°C,  incomplete at 22°C,  and did not occur at O°C. 
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FIG. 3. Inhibition of antigenic modulation by actinomycin D. Step 1. Incubation of RADA1 
(TL.1,2,3)  leukemia cells in actinomycin D--cells then washed twice in the cold. 
Step 2. Incubation in anti-TL.1,3 serum 1/320 for 1~ hr--cells then washed twice in the 
cold. 
Step 3.  This figure.  Cytotoxic tests with anti-TL.1,3  serum. 
Curves for sensitivity to C' alone (not shown) were similar to those in this figure. Controls 
in which normal mouse serum was substituted /or TL  antiserum in step  2  were included 
for every point; these showed normal sensitivity to TL antibody and C' and no sensitivity 
to C' alone. 
Modulation is completely  inhibited by exposure of calls to 5 #g  actinomycin D/ml for 1 hr 
and is partially inhibited by lower concentrations  or shorter periods of incubation. OLD~  STOCKERT, BOYSE, AND KIM  529 
(0.5 mg/ml and 1 mg/ml); cycloheximide (10 Izg/ml and 20 gg/ml); deoxy- 
adenosine (0.5 mg/ml); 5-fluorodeoxyuridine (FUDR 1 Izg/ml); 1-~-D-arabino- 
furanosylcytosine (ara-C;  10 /~g/ml and 20  #g/ml); hydrocortisone  21-phos- 
phate, disodium salt (0.5 mg/ml and 1 mg/ml). Four of these inhibitors  were 
tested for their influence on DNA,  RNA,  and protein synthesis in RADA1 
cells (under the same  conditions  as those  used for testing their influence on 
modulation) as indicated by rates of incorporation  of tritium-labeled precur- 
sors. As anticipated, actinomycin D  produced  major and immediate suppres- 
sion of RNA synthesis, followed by suppression of DNA and protein synthesis 
becoming virtually complete  at 2 hr.  The most immediate and pronounced 
effect of iodoacetamide  (a potent inhibitor of SH-containing  enzymes) in the 
1st hr, was on DNA synthesis, with moderate depression of protein synthesis, 
and little effect on RNA synthesis.  FUDR curtailed DNA synthesis immedi- 
ately, with virtually no effects on RNA and protein synthesis during a period 
of 4  hr. At concentrations near the toxic level for RADA1  cells puromycin 
gave  only moderate  suppression  of  protein  and  RNA  synthesis,  therefore 
little significance can be attached to the results obtained with this agent. The 
results with FUDR and ara-C  permit the conclusion that modulation is not 
dependent on DNA synthesis; from the results with actinomycin D there is a 
strong indication that RNA synthesis is necessary; adequate evaluation of the 
necessity  for protein  synthesis awaits  evidence  as  to  whether  the  relevant 
compounds  used in this study in fact selectively  inhibit protein synthesis in 
RADA1 cells. 
None of the metabolic  inhibitors affected the sensitivity of the cells to TL 
antibody and C' in the cytotoxic test, as might be the case if the turnover of 
TL antigen were rapid and maintenance of the TL phenotype therefore highly 
dependent on  continuous synthesis of protein  or nucleic  acid.  Exposure  of 
modulated RADA1  cells to  actinomycin D  did not  cause  reversion  of the 
phenotype to TLq-.  Thus the TL--  phenotype, once induced,  is  stable,  at 
least over a period of 4 hr. 
5000 R X-radiation had no effect on the capacity of RADA1 cells to modu- 
late. 
Synthesis of DNA, RNA, and Protein in Cells Undergoing Modulation.- 
Antigenic  modulation was  not  accompanied  by demonstrable  changes  in 
net synthesis of DNA,  RNA, or protein, as tested by uptake of radioactive 
precursors  over periods of 15 rain to 4 hr, although this does not exclude dis- 
crete  changes in the synthesis of particular products which may be obscured 
by the exceedingly high metabolic  activity of these leukemia cells. 
Modulalion of TL Antigens by TL Antisera of Various Specificities.-- 
The four TL antisera available  are anti-TL.1,2,3; anti-TL.1,3;  anti-TL.2; 
and anti-TL.3  (Table  III). So far it has not been possible to prepare  mono- 530  ANTIGENIC  MODULATION 
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FIG. 4.  Cytotoxic  tests  with  RADA1  (TL.1,2,3)  leukemia  cells  previously  incubated 
for  1N  hr  with  anti-TL.3  serum.  (NMS,  normal  mouse  serum.) 
As a consequence of exposure to anti-TL.3 serum the cells are no longer sensitive to anti-TL.1, 
anti-TL.2, or anti-TL.3. 
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Fzc.  5.  Cytotoxic tests with RADA1  (TL.1,2,3)  leukemia cells previously incubated for 
11/~ hr in normal mouse serum (NMS),  in anti-TL.1,3  serum, or anti-TL.2  serum. 
TL.2  is  not  modulated  by  anti-TL.2. 
specific anti-TL.1.  In previous experiments in vivo (5), TL.1,2,3  cells were 
completely modulated by anti-TL.1,3  serum,  indicating  that  modulation of 
TL.2 takes place as a consequence of modulation of TL.1 and 3 and does not 
require the presence of anti-TL.2. In the following experiments with RADA1 
cells the various TL antisera were tested for their capacity to modulate TL 
antigens of both homologous and nonhomologous specificity. 
Modulation  of all TL components by anti-TL.3: The preparation of anti-TL.3 
serum is given in Table III.  No  residual TL.1  antibody can be detected in 
this serum in cytotoxic tests with the standard TL.1 test cell ERLD. Never- OLD, STOCKERT, BOYSE~ AND  KIM  531 
theless in order to ensure absence of anti-TL.1  the serum used for modulation 
in the experiment  shown in Fig. 4 was absorbed  a second time in C57BL/6 
mice bearing leukemia ERLD (see Table III). This doubly absorbed anti-TL.3 
serum produced modulation of all three components, TL.1, TL.2 and TL.3. 
Inability of anti-TL.2 to induce modulation: Preincubation of RADA1 cells 
with anti-TL.2 serum did not produce modulation of TL.2 (Fig. 5). 
Although it may be presumed  that TL.1 and TL.3 antigens also are not 
modulated by anti-TL.2,  this is difficult to demonstrate directly. In the first 
place, cells sensitized by anti-TL.2  do not modulate and consequently remain 
susceptible to C' lysis; they therefore cannot be used in direct cytotoxic tests 
with anti-TL.1,3  serum.  Furthermore, anti-TL.2  partially blocks the uptake 
of these  antibodies,  which complicates  the demonstration of TL.1 and TL.3 
antigens by the method of absorption (the cells having already taken up anti- 
TL.2). However the possibility  that TL.1 and TL.3 might be modulated by 
anti-TL.2  is rendered  remote by the observation  that addition of anti-TL.2 
actually impedes modulation by anti-TL.1,3  serum  (see below). 
Inhibition  of Antigenic Modulation by Anti-TL.2 Serum.- 
It was noted that anti-TL.1,3  serum was consistently more effective than 
anti-TL.1,2,3  serum  in inducing  modulation in vitro. For this reason  most 
experiments  were performed with anti-TL.1,3  serum. The subsequent  finding 
that anti-TL.2  is incapable  of inducing modulation suggested  that the rela- 
tively poor modulating capacity of anti-TL.1,2,3 serum might be attributable 
to its anti-TL.2 content. Fig. 6 shows that this interpretation is correct.  Re- 
moval of anti-TL.2  from an anti-TL.1,2,3  serum  by absorption with TL.2 
thyrnocytes  rendered it as effective as the standard anti-TL.1,3 serum. Control 
absorption with TL--  thymocytes had no effect. In other experiments  it has 
been  shown  that preincubation with anti-TL.2  serum  renders  RADA1  ceils 
less sensitive to modulation by anti-TL.1,3 serum. 
Changes in H-2 Antigen Accompanying Antigenic Modulation.- 
Antigenic modulation of TL+ leukemia cells in vivo results  in an increase 
in demonstrable H-2 antigen (5). H-2 is a compound locus determining a series 
of antigens (9). "D" and "K" are the original designations of two strong H-2 
antigens determined by opposite poles of the locus, the two ends of the locus 
therefore being referred  to as the D  end mad the K end. With respect  to Tla 
the order is Tla:H-2(D):tt-2(K)  (1, 10). 
Cells undergoing modulation in vitro also showed the increase in H-2 anti- 
gen (Fig. 7) and this was confined to H-2(D) antigen with no change in H-2(K) 
antigen. Modulation of TL antigen was apparently complete in approximately 
1 hr, but the H-2(D) content of the cells continued to rise for 4~ hr. 532  ANTIGENIC  MODULATION 
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anti-TL.2 or lacking anti-TL.2.  (NMS, normal mouse serum.) 
The modulating  capacity  of an anti-TL.1 ,Z,3 serum ~s increased by first absorbing out anti- 
TL.2, 
~80-- 
L,J 
=~  60 
_---  20 
0  - 
en '~ 
Modulation 
o  .21K en  . 
~  v  v  ,  - 
I  I  I  I  I  ,,,I 
1  2  3  4  5  6 
Period of preincubation  at 37  ° C  in TL antiserum  (hours) 
g 
-1.8  ~- 
1.4 ~ 
g~ 
-~1.0 
FIG. 7. When antigens TL.1,2,3 of RADA1 leukemia cells are suppressed  by TL antibody 
(antigenic modulation) H-2  isoantigens of the D  region are increased in ~mount, but H-2 
isoantigens of  the  K  region are not affected.  (For calculation of  relative H-2  absorption 
capacity see Materials and Methods). "'""- 8' ~  ~  ~ 
I /  ',I i 
1  l  ,s  ii~ 
T  I  7  ~ 
8  A  ~//~o 
¢"~  o  /  J 
t  I  I  I  I 
peep  Slle3  % 
.LS  ].L 31XO.LO.I.AD 
533 
•  ~  ~,~  o_ 
_~o  ~.~ 
°~  ~  ~ 
o.o~ 
•  -  o  ~.  N.~.= 
_~-~-~ ~.~  ~ 
¢0  O,~q= 
0"~  o  -o 
~m  N 534  ANTIGENIC  MODULATION 
Restoration  of TL Phenotype after Antigenic Modulation.- 
It  was  known  from previous  work  that  modulated  cells  from  immunized 
hosts become TL+  again when passed in nonimmunized hosts (4) but the rate 
of reversion  was unknown  except for  the  observation  that  it  could  be  com- 
pleted  during  a  single  passage  in  a  nonimmune  mouse.  With  the  object  of 
determining  how  rapidly  the  TL+  phenotype  returns,  RADA1  cells  modu- 
lated  in  vivo were washed four times to remove TL antibody present in  the 
ascitic fluid and then were cultured in vitro (Fig.  8). Some restoration of sen- 
sitivity to TL antibody was apparent after 24 hr in culture and by 7 days the 
cells  were  indistinguishable  from unmodulated  cells  by  the  direct  cytotoxic 
test with TL antibody. The average doubling time of RADA1  cells in culture, 
whether modulated or not,  is  18-24 hr. Thus the  cells underwent  six or more 
divisions before TL antigenicity was fully restored. A line of the original modu- 
lated cells was maintained in medium to which  1/1000 anti-TL.1,3  serum had 
been added.  These remained completely TL--. After 5  days in culture,  anti- 
body was omitted and the cells became TL+,  in this case more rapidly (Fig. 
8). Unmodulated RADA1 cells showed no change in sensitivity to TL antibody 
in the cytotoxic test as a  result of culture in vitro (Fig. 8). 
DISCUSSION 
Antigenic  modulation was first observed in TL+  leukemias inoculated into 
actively immunized TL--  hosts of the strain of origin (4). Passive immuniza- 
tion with TL antiserum was then shown to be effective in inducing modulation 
and  this  revealed  that  both  TL+  thymocytes and TL+  leukemias of TL+ 
strain mice (which cannot be actively immunized) are susceptible to antigenic 
modulation  (5).  The  process  can  now  be  studied  in  vitro,  eliminating  the 
difficulties of analysis in vivo. Several factors are seen to influence modulation 
of TL antigen in vitro. 
Cell Type  on which the Antigen  is Situated.--Of  the  two  cell  types bearing  TL 
antigen,  TL +  thymocytes and  TL+  leukemia  cells, modulation in  vitro is  more 
readily demonstrable in the latter. Under similar conditions  thymocytes also undergo 
modulation, but only partially and after longer periods  of incubation, although com- 
plete  antigenic  modulation of thymus cells  can be produced in vivo by transfer of 
TL antiserum  (5). There are also differences among various TL +  leukemias in the 
rate at which they undergo modulation. These pronounced differences in modulation 
rate,  according  to  cell type, suggest  that  modulation  is  an  active  cellular  process 
occurring most rapidly in cells with high metabolic activity. 
Metabolic State of the Cells.--The  conclusion  that modulation is an active cellular 
process is borne out by its abolition at reduced  temperature, by actinomycin D  and 
by  iodoacetamide.  (Inhibition  of  DNA  synthesis  did  not  abolish  modulation;  the 
interpretation  of the  results with inhibitors  of protein  synthesis is  not  clear; more 
data are required  on the influence  of these compounds on protein  and nucleic  acid 
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Concentration o.f  TL  Antibody.--The  rapidity  of  modulation  is  independent  of 
antibody concentration over a wide range. At limiting dilutions  of antiserum it may 
occur in the absence of concomitant sensitization  to C  I. The quantity  of antibody 
required for modulation therefore is presumably less  than that needed  to sensitize 
the cell to lysis by C r under the specified conditions  of the cytotoxic test. The impli- 
cation is that modulation can take place although not every TL site on the cell is 
occupied  by antibody, but this has not yet been critically demonstrated. 
Specificity of TL Antibody.--Cells  of the phenotype TL.1,2,3 become TL-  when 
exposed  to anti-TL.3, showing  that modulation of components TL.1  and TL.2 can 
occur despite absence of corresponding antibody from the serum used for modulation. 
All three TL specificities may well be on one molecule (11) in which  case modulation 
may be envisaged as loss of this entire molecule following the attachment of antibody. 
On the other hand,  the attachment of TL antibody to this site does not inevitably 
entail modulation, because anti-TL.2 does not induce modulation, in fact the attach- 
ment of anti-TL.2 hinders modulation. Monospecific anti-TL.1 serum is not available 
and  so its capacity to modulate TL.2  and TL.3 is unknown.  However, as TL.1,2 
leukemias of TL-  strains are modulated by anti-TL.1,3 it is clear that TL.1 and 2 
are modulated by anti-TL.1. It seems self-evident  that anti-TL.3 cannot modulate 
a TL.1,2  cell, there being no site for attachment of antibody. Thus anti-TL.3 can 
modulate TL.1 if it can be attached to the cell (Fig.  4)  but  in  the  case of TL.1,2 
cells this is not so. Modulation of TL.1 in TL.1,2 cells can therefore safely be ascribed 
to anti-TL.1. 
Many features of modulation exclude passive mechanisms such as blocking 
of TL antigenic sites by antibody that lacks complement-fixing properties and 
consequently is not lytic (12).  This and other passive mechanisms, including 
antibody-induced resistance of red cells to immune lysis (13), are ruled out by 
several  observations.  (a)  Over  a  wide  range  of TL  antibody  concentrations 
the cells are fully sensitized before they undergo modulation. Thus the fixation 
of lyric antibody is demonstrably not blocked. The only known ways of pro- 
ducing modulation  without  an  initial  transient  phase  during  which  the  cells 
are sensitive to lysis by C' are to use low concentrations of TL antibody that 
suffice for modulation but sensitize to C t only weakly or not at all, or to use 
antibody fragments that do not bind CP.  1 (b) TL antigens 1 and 2 of TL.1,2,3 
cells are modulated by antiserum lacking specificities 1 and 2. It is improbable 
that anti-TL.3  could  block the attachment of lyric anti-TL.1, in fact we have 
found that attachment of anti-TL.3 does not impede absorption of anti-TL.1 
(unpublished data).  (c) As described above, modulation is strongly depressed 
by thermal or chemical inhibition of metabolic activity, and its rate depends 
upon the type of cell which is carrying the TL antigens, all of which is not in 
keeping  with  blocking  by  antibody.  (d)  Application  of  fluorescein-labeled 
1  Lamm, M., E. A. Boyse, L. J. Old, B. Lisowska-Bernstein, and E. Stockert. 1968. Modu- 
lation of TL  (thymus-leukemia) antigen by Fab-fragments of  TL  antibody.  Manuscript 
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antiglobulin  serum  has  shown  that  cells  modulated in  vivo,  in  actively or 
passively immunized hosts, are not coated with globulin (unpublished data). 
(e) Modulated cells show a  selective increase in H-2(D)  antigen which is not 
explicable in terms of blocking antibody. 
Antigenic modulation can therefore be viewed confidently as an actual loss 
of TL components from the cell surface. 
Another mechanism now excluded by the rapidity of modulation in vitro is 
the selection of a TL-- fraction of the population. Modulation in vitro cannot 
be other than an adaptive change affecting the cell population as a whole. 
An apparently close parallel to antigenic modulation is the serotype trans- 
formation which takes place in Paramecia exposed to various changes in their 
environment, in particular to  type-specific antiserum (14).  As with modula- 
tion,  the  serotype change is  adaptive rather  than selective and depends on 
active metabolism. In both phenomena the lost antigen is the product of a 
known gene and in neither case is loss of the antigen brought about by genetic 
mutation. Nevertheless there are  clear differences between the two systems. 
Serotype change in Paramecia  can be induced by factors other than antibody 
(temperature,  nutritional deficit, X-radiation,  chemical agents),  it proceeds 
relatively slowly over a  period  of several cell  divisions, and  it involves the 
appearance of a  formerly unexpressed alternative antigen. Antigenic modula- 
tion in contrast can be induced only by antibody (as far as is known), it occurs 
rapidly and independently of cell division, and it is not accompanied by the 
appearance of a new antigen (the change in H-2 antigen accompanying modu- 
lation being only quantitative, and even this may be only apparent, for it may 
possibly result from removal of steric interference imposed upon the H-2(D) 
site by TL components of the membrane). 
Modulation has not been observed in other systems of isoantigens and so 
appears to be peculiar to TL. A second unique feature of the TL system is the 
anomalous appearance of antigen in strains of mice that do not possess  it in 
normal  tissue  (TL--  strains).  Whereas  modulation  is  characteristic  of  TL 
antigens as a class, all three components being capable of modulation, anoma- 
lous appearance in leukemia cells of TL--  mice is restricted to antigens TL.1 
and TL.2. Thus TL.3 antigen can undergo modulation but it never appears in 
leukemias of mice that are TL.3 negative. In fact each of the three components 
has distinctive properties, which are summarized in Table IV. 
The appearance of TL.1 and TL.2 antigens in the teukemias of probably all 
mouse strains implies that structural genes for these antigens are present in 
all mice, the phenotype being governed by the locus identified in linkage group 
IX,  Tla,  which has alleles  for expression vs. nonexpression of structural TL 
genes. As there can be no alleles of the TL.1 and TL.2 structural genes it fol- 
lows that normal TL--  mice not only lack antigens TL.1 and TL.2 but have 
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pretation is supported by the finding that the content of H-2(D)  antigen in 
TL--  thymocytes is higher  than in TL+  thymocytes of the same H-2 type 
(5). 
Expression of TL in thymocytes  depends not only on their genotype but 
also upon residence in the thymus, since TL+ cells are not found elsewhere. 
Experiments with chimeras show that the thymic environment of TL-- mice 
induces expression of TL in thymocytes of appropriate genotype and so the 
ths~nic influence presumably is common  to all mice  (1, 3).  It is not known 
whether expression of TL antigen is a secondary consequence of the differen- 
tiation of immigrant cells within the thymus or whether the T/a locus is directly 
activated by a thymic factor. Whatever the explanation the persistence of the 
TL phenotype in disseminated  leukemia  cells indicates  that they no longer 
depend upon the thymus for expression of TL. This is further emphasized by 
TABLE IV 
Distinctive Properties of the Three TL Antigens 
Antigen  Modulation by the  Modulation by non-  Anomalous appearance 
homologous antibody  homologous antibody  in ieukemta cells 
TL.1  +  -b  + 
TL.2  --  +  + 
TL.3  +  ?  -- 
the retention of TL antigen by leukemia cells in continuous culture, an obser- 
vation indicating also that TL antigens are not acquired  secondarily  in the 
manner of such  blood  group  antigens as Lewis in man and J  in cattle (see 
reference 15). 
It  is evident  that  both  intracellular and  environmental factors  regulate 
expression of TL. One of the two known external factors, the thymic influence, 
appears  as  a  physiological  regulator of TL expression in normal cells. The 
significance of the other, TL antibody, is unknown in the context of normal 
physiology,  although reasons have been given for the conclusion that it is not 
the physiological suppressor of TL antigen in the thymus of TL-- strains (1). 
With regard  to internal control we must recognize both the maintenance of 
the TL-- phenotype in a/l cells outside the thymus and also the retention of 
the TL--  phenotype by thymocytes themselves in mice of those strains that 
are  TL--.  Both manifestations of control  are  lost in TL+  leukemias,  the 
TL+ phenotype now being expressed in cells outside the thymus and in mice 
whose normal thymocytes are TL--. 
Little can be said at the moment about the mechanism by which TL anti- 
body brings about the phenotypic change TL+ --* TL--. The initiating event 
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scarcely be any doubt, but how this leads to loss of the antigen is unknown. 
A  critical  question  is  whether modulation  at  a  particular  site  requires  the 
attachment of antibody to that site or whether modulation of a/l sites on a 
cell can be initiated by attachment of antibody to only some of them. The first 
of these possibilities implies a  surface mechanism in which antibody fixation 
leads to release of antigen,  which is  either exfoliated or drawn into the cell. 
The second implies the setting in train of cellular events which lead to reversal 
of  the  phenotype.  The  dependence  of modulation  on  metabolic  processes, 
manifested by its abolition at low temperature and by actinomycin D, does 
not especially favor either mechanism as both might require continuation of 
adequate cellular metabolism. 
SUMMARY 
Antigenic modulation (the loss of TL antigens from TL+  cells exposed to 
TL antibody in  the absence of lyric complement) has been demonstrated in 
vitro.  An  ascites  leukemia,  phenotype  TL.1,2,3,  which  modulates  rapidly 
and completely when incubated with TL antiserum in vitro, was selected for 
further study of the phenomenon. Over a wide range of TL antibody concen- 
trations modulation at 37°C was detectable within  10 min and was complete 
within approximately 1 hr.  The cells were initially sensitized to C t by their 
contact with  antibody,  thereafter losing  this sensitivity to  C t  lysis together 
with their sensitivity to TL antibody and C' in the cytotoxic test. The capacity 
of the cells to undergo modulation was  abolished by actinomycin D  and by 
iodoacetamide, and by reducing the temperature of incubation to 0°C. Thus 
modulation apparently is an active cellular process. Antigens TL.1,2, and 3 
are all modulated by anti-TL.1,3  serum and by anti-TL.3 serum. This modu- 
lation affects all three TL components together, even when antibody to one 
or two of them is lacking. Anti-TL.2 serum does not induce modulation and in 
fact impairs modulation by the other TL antibodies. The influence of the TL 
phenotype of cells upon the demonstrable content of H-2 (D region) lsoantigen, 
first shown in cells modulated in vivo, has been observed with cells modulated 
in vitro.  Cells undergoing modulation show a  progressive increase in H-2  (D 
region) antigen over a period of 4 hr, with no change in H-2 antigens of the K 
region. Restoration of the TL+  phenotype of modulated cells  after removal 
of antibody is  less  rapid  than  TL+  --+  TL--  modulation and may require 
several cell divisions. 
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